Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC36344 structure
    GC36344Isosilybin B
    CAS: 142796-22-3

    Isosilybin B,一种从 silymarin 中分离的黄酮木脂素,具有抗前列腺癌 (PCA) 活性,抑制癌细胞增殖,诱导 G1 期阻滞和凋亡。Isosilybin B 引起雄激素受体降解。

  • GC36390 structure
    GC36390Keap1-Nrf2-IN-1
    CAS: 2232112-72-8
    纯度: >98.00%

    Keap1–Nrf2 IN-1 (compound35) 是一种 Keap1- nrf2 蛋白-蛋白相互作用抑制剂,对 Keap1 蛋白作用的 IC50 值为 43 nM。Keap1–Nrf2 IN-1 (compound35) 能激活 Nrf2 调节的细胞保护反应,并在细胞和体内模型中对乙酰氨基酚诱导的肝损伤产生拮抗作用。

  • GC36393 structure
    GC36393Kinetin riboside
    CAS: 4338-47-0
    纯度: >98.00%

    An anticancer nucleoside

  • GC36424 structure
    GC36424Larotaxel
    CAS: 156294-36-9

    Larotaxel (XRP9881) 是一种紫杉烷类似物,具有抗紫杉烷抗性乳腺癌的临床前活性。Larotaxel (XRP9881) 通过促进微管蛋白装配和稳定微管发挥其细胞毒性作用,并最终通过细胞凋亡导致细胞死亡。Larotaxel (XRP9881) 具有穿越血脑屏障的能力,对 P-糖蛋白 1 的亲和力比 Docetaxel 低得多。

  • GC36434 structure
    GC36434Leachianone A
    CAS: 97938-31-3

    Leachianone A 从槐花中分离,具有抗疟疾,抗炎和细胞毒性作用。Leachianone A 诱导细胞凋亡 (apoptosis)。

  • GC36456 structure
    GC36456Licoricidin
    CAS: 30508-27-1

    Licoricidin (LCD) 从甘草 Glycyrrhiza uralensis Fisch 中分离,具有抗癌活性。Licoricidin (LCD) 通过诱导周期停滞,诱导细胞凋亡 (apoptosis) 和自噬 (autophagy),是一种对抗结直肠癌的潜在化学预防或化学治疗剂。Licoricidin (LCD) 通过抑制肿瘤血管生成和淋巴管生成以及肿瘤组织局部微环境的变化抑制肺转移。Licoricidin (LCD) 通过体外和体内 Akt 和 NF-κB 途径的失活,增强吉西他滨诱导的骨肉瘤 (OS) 细胞的细胞毒性。Licoricidin (LCD) 通过 ROS 清除阻断 UVA 诱导的光老化,限制 MMP-1 的活性,被认为是新的局部应用的抗衰老制剂中的活性成分。

  • GC36488 structure
    GC36488Lucidenic acid B
    CAS: 95311-95-8

    Lucidenic acid B 是从灵芝中分离得到的天然产物,可诱导肿瘤细胞凋亡,可产生 caspase-9 和 caspase-3 的活化和 PARP 的裂解。Lucidenic acid B 对细胞周期没有影响,且对坏死细胞无作用。

  • GC36516 structure
    GC36516Lycopodine
    CAS: 466-61-5

    Lycopodine,一种石松 (Lycopodium clavatumspores) 孢子重要的生物活性成分,通过调节难治性前列腺癌细胞中 5-脂氧合酶 (5-lipoxygenase),极化线粒体膜电位而不调节 p53 活性来诱导细胞凋亡。 Lycopodine 通过激活 caspase-3 诱导细胞凋亡来抑制 HeLa 细胞的增殖。

  • GC36542 structure
    GC36542MARK4 inhibitor 1
    CAS: 2271081-58-2
    纯度: >98.00%

    MARK4 inhibitor 1是微管亲和力调节激酶4(MARK4)的强效抑制剂,对MARK4的IC 50 值为1.54±0.22μM。

  • GC36546 structure
    GC36546Masitinib mesylate
    CAS: 1048007-93-7
    纯度: >99.50%

    An inhibitor of c-Kit

  • GC36552 structure
    GC36552MBM-17
    CAS: 2083621-90-1

    MBM-17 (compound 42c) 是有效的 NIMA-related kinase 2 (Nek2) 抑制剂,IC50 值为 3 nM,通过诱导细胞周期停滞和凋亡,抑制癌细胞的增殖,具有抗肿瘤活性,且对小鼠没有明显的毒性。

  • GC36553 structure
    GC36553MBM-55
    CAS: 2083622-09-5

    MBM-55 (compound 42g) 是有效的 NIMA-related kinase 2 (Nek2) 抑制剂,IC50 值为 1 nM,是其他激酶选择性的 20 倍甚至更高,除了 RSK1 (IC50=5.4 nM) 和 DYRK1a (IC50=6.5 nM)。MBM-55 通过诱导细胞周期停滞和凋亡抑制癌细胞的增殖。具有抗肿瘤活性,且对小鼠没有明显的毒性。

  • GC36556 structure
    GC36556Mcl1-IN-1
    CAS: 713492-66-1
    纯度: >98.00%

    Mcl1-IN-1 是一种骨髓细胞因子 1 (Mcl-1) 抑制剂,IC50 为 2.4 ?M。

  • GC36557 structure
    GC36557Mcl1-IN-11
    CAS: 2042211-13-0

    Mcl1-IN-11 (Compound G) 是一种选择性的 Mcl-1 抑制剂,对 Bcl-2 的作用较弱,Ki 值分别为 0.06 和 4.2 μM。

  • GC36558 structure
    GC36558Mcl1-IN-12
    CAS: 2042211-12-9

    Mcl1-IN-12 (Compound F) 是一种选择性的 Mcl-1 抑制剂,对 Bcl-2 的作用较弱,Ki 值分别为 0.29 和 3.1 μM。

  • GC36559 structure
    GC36559Mcl1-IN-9
    CAS: 1810769-31-3

    Mcl1-IN-9 是一种有效的髓细胞白血病基因 1 (Mcl-1) 抑制剂,在重组的 BCR-ABL+ B-ALL 细胞中的 IC50 值为 446 nM,Ki 值为 0.03 nM。

  • GC36605 structure
    GC36605MI-1061
    CAS: 1410737-34-6
    纯度: >99.50%

    MI-1061 是一种有效的,口服可生物利用的,化学稳定性的 MDM2 (MDM2-p53 互作) 抑制剂 (IC50=4.4 nM; Ki=0.16 nM)。MI-1061 能有效激活 p53,诱导细胞凋亡,并具有抗肿瘤活性。

  • GC36612 structure
    GC36612Minnelide
    CAS: 1254702-87-8
    纯度: >99.50%

    Minnelide 是雷公藤内酯的衍生物,在许多肿瘤类型 (特别是在胰腺癌) 中显示出抗肿瘤 (antitumor) 活性。 Minnelide 可导致凋亡 (apoptotic)。

  • GC36613 structure
    GC36613Minodronic acid
    CAS: 180064-38-4
    纯度: >98.00%

    Minodronic acid (YM529, ONO-5920) is a third-generation nitrogen-cotaining bisphosphonate that is used for the treatment of osteoporosis. Minodronic acid is an aminobisphosphonate that is a selective antagonist of purinergic P2X2/3 receptors involved in pain.

  • GC36619 structure
    GC36619MitoTam bromide, hydrobromide
    CAS: 1634624-73-9

    MitoTam bromide, hydrobromide 他莫昔芬衍生物,它是一种电子传递链 (ETC) 抑制剂,抑制衰老细胞中的线粒体膜电位变化并影响线粒体形态。MitoTam bromide, hydrobromide 是一种有效的抗癌剂,可以抑制乳腺癌细胞中呼吸复合物 (CI- respiration) 和超复合物 (SCs) 的形成。MitoTam bromide, hydrobromide 诱导细胞凋亡 (apoptosis)。

  • GC36620 structure
    GC36620MitoTam iodide, hydriodide
    CAS: 1634624-74-0

    MitoTam iodide, hydriodide 他莫昔芬衍生物,它是一种电子传递链 (ETC) 抑制剂,抑制衰老细胞中的线粒体膜电位变化并影响线粒体形态。MitoTam iodide, hydriodide 是一种有效的抗癌剂。MitoTam iodide, hydriodide 抑制乳腺癌细胞中呼吸复合物 (CI- respiration) 和超复合物 (SCs) 的形成。MitoTam iodide, hydriodide 可以诱导细胞凋亡 (apoptosis)。

  • GC36652 structure
    GC36652MPT0B392
    CAS: 1346169-92-3

    MPT0B392 是一种口服活性的喹啉衍生物,作用于 c-Jun N末端激酶 (JNK) 和 apoptosis 的激活剂。MPT0B392 抑制微管蛋白聚合,通过激活 JNK 诱导细胞有丝分裂停滞,线粒体膜电位丧失和 caspases 裂解,最终导致细胞凋亡。MPT0B392 是一种新型微管解聚剂,可增强西罗莫司对耐药急性白血病细胞和多药耐药细胞系的细胞毒性。

  • GC36690 structure
    GC36690Nampt-IN-3
    CAS: 2121591-52-2
    纯度: >99.00%

    Nampt-IN-3 (Compound 35) 同时抑制烟酰胺磷酸核糖转移酶 (NAMPT) 和 HDAC,IC50 分别为 31 nM 和 55 nM。Nampt-IN-3 有效诱导细胞凋亡 (apoptosis) 和自噬 (autophagy),最终导致细胞死亡。

  • GC36711 structure
    GC36711Necrostatin 2 racemate
    CAS: 852391-15-2
    纯度: >99.50%

    Necrostatin 2 racemate是一种不影响吲哚胺2,3-双加氧酶(IDO)活性的,具有高度特异性的受体相互作用蛋白激酶1(RIPK1)抑制剂。